Showing 5761-5770 of 8818 results for "".
- UofL Dermatology Chief Tapped by ACCMEhttps://practicaldermatology.com/news/uofl-dermatology-chief-tapped-by-accme/2458477/Jeffrey P. Callen, MD, chief of the Division of Dermatology at the University of Louisville School of Medicine in Kentucky, has been elected to serve on the Accreditation Review Committee (ARC) of the Accreditation Council of Continuing Medical Education (ACCME).
- BTL Aesthetics Announces FDA Clearance for Thighshttps://practicaldermatology.com/news/btl-aesthetics-announces-fda-clearance-for-thighs/2458475/The FDA awarded BTL Aesthetics a new designation for it non-invasive fat reduction treatment, BTL Vanquish ME—the treatment is now FDA-cleared for the circumferential reduction of the abdomen and thighs. The clearance was secured following several rounds of clinical testing to provide ample
- MRF to UPSTF: Reconsider Supporting Annual Skin Cancer Checkshttps://practicaldermatology.com/news/mrf-to-upstf-reconsider-support-for-annual-skin-cancer-checks/2458479/The Melanoma Research Foundation (MRF) is urging the U.S. Preventive Services Task Force’s (USPSTF) to reconsider their recent announcement stating that insufficient data exists to support a recommendation for annual skin canc
- Meeting Pearls and More: Don't Miss DermTube's Summer AAD Coveragehttps://practicaldermatology.com/news/dont-miss-dermtubes-summer-aad-coverage/2458481/Don’t Miss DermTube’s upcoming coverage of the Summer American Academy of Dermatology (AAD) Meeting in Boston. Summer AAD takes place from July 28-31, 2016. Hosted by Seemal R. Desai, MD
- ASDS Disagrees with New Skin Cancer Screening Recommendationhttps://practicaldermatology.com/news/asds-disagrees-with-new-skin-cancer-screening-recommendation/2458483/The US Preventive Service Task Force (USPSTF) has declined to take a stance on the value of preventive skin cancer screenings for the second time in seven years, and The American Society for Dermatologic Surgery ASDS is responding with disappointment. The USPSTF says there is insufficient
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien